Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 124) Show all publications
Metcalfe, J. Z., Weir, I. R., Scarsi, K. K., Mendoza-Ticona, A., Pierre, S., Hall, L., . . . Chaisson, R. (2026). A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. The Lancet - Infectious diseases, 26(1), 46-54
Open this publication in new window or tab >>A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
Show others...
2026 (English)In: The Lancet - Infectious diseases, ISSN 1473-3099, E-ISSN 1474-4457, Vol. 26, no 1, p. 46-54Article in journal (Refereed) Published
Abstract [en]

Background Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis. Methods Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries. Participants aged 18 years or older with pulmonary tuberculosis who were sputum smear positive for acid-fast bacilli or molecular tuberculosis assay positive (with Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid) were eligible for enrolment. Individuals with HIV infection with a CD4+ cell count >= 100 cells per mm3 could participate. Participants were randomly assigned in a 2:1 ratio (group 1: group 2) or a 2:1:1 ratio (group 1: group 2: group 3), depending on consent to participate in the intensive pharmacokinetic visits required in group 3, using a central web-based system with permuted blocks. The group 1 regimen included 8 weeks of rifapentine-isoniazid-pyrazinamide-ethambutol-clofazimine, with a 2-week 300 mg clofazimine loading dose, followed by 5 weeks of rifapentine-isoniazid-pyrazinamide-clofazimine (13 weeks total). The group 2 control regimen included 8 weeks of isoniazid-rifampicin-pyrazinamide-ethambutol followed by 18 weeks of rifampicin-isoniazid. Group 3 was identical to group 1 over the first 4 weeks of treatment, except that the regimen was administered without a clofazimine loading dose (100 mg daily); after 4 weeks of group 3 treatment, participants transitioned to local standard of care to complete treatment. Group 3 was designed to assess the effect of a 2-week loading dose on clofazimine pharmacokinetics. Randomisation was stratified by HIV status and advanced disease on chest radiograph. The primary efficacy endpoint was time to sputum culture-negative status by 12 weeks. The primary safety endpoint was the proportion of participants experiencing any grade 3 or worse adverse event over 65 weeks. The key secondary endpoint was unfavourable clinical or bacteriological outcomes by week 65. The efficacy analysis population contained participants assigned to groups 1 and 2 who were not late exclusions (no positive culture at screening, entry, or week 1, or if rifampicin resistance or isoniazid resistance was detected at screening or entry); the safety analysis population contained all randomly assigned participants who took at least one dose of treatment. The trial was registered with ClinicalTrials.gov ID: NCT04311502. Findings 104 participants were randomly assigned to group 1 (n=58), group 2 (n=31), and group 3 (n=15). 82 (79%) were male and 74 (71%) had radiographically advanced disease; 30 (29%) were people with HIV. The trial was stopped early for lack of clinical efficacy. For the primary efficacy outcome, 49 (89%) of 55 group 1 participants and 28 (90%) of 31 group 2 participants had stable sputum culture conversion by week 12 (adjusted hazard ratio 1<middle dot>21 [90% CI 0<middle dot>82-1<middle dot>79]; p=0<middle dot>2089). Adverse events grade 3 or worse occurred in 26 (45%) of 58 group 1 participants and five (16%) of 31 group 2 participants (difference 30%, 90% CI 14-45; p=0<middle dot>002). The cumulative probability of a week 65 unfavourable outcome was 52% (95% CI 37-69) in group 1 versus 27% (14-50) in group 2 (p=0<middle dot>049). Interpretation Although the trial was stopped early, we found that a 3-month regimen containing clofazimine and rifapentine had 12-week culture conversion rates that did not differ statistically from the standard of care. The regimen was associated with an unacceptably high proportion of participants with unfavourable composite clinical outcomes and grade 3 or worse adverse events.

Place, publisher, year, edition, pages
Elsevier, 2026
National Category
Infectious Medicine Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-576085 (URN)10.1016/S1473-3099(25)00436-0 (DOI)001645618900001 ()40915311 (PubMedID)2-s2.0-105016894020 (Scopus ID)
Available from: 2026-01-15 Created: 2026-01-15 Last updated: 2026-01-15Bibliographically approved
Lin, Y.-J., Okibedi, F., Karlsson, M. O. & Svensson, E. M. (2026). An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis. CPT: Pharmacometrics and Systems Pharmacology (PSP), 15(5), Article ID e70264.
Open this publication in new window or tab >>An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis
2026 (English)In: CPT: Pharmacometrics and Systems Pharmacology (PSP), E-ISSN 2163-8306, Vol. 15, no 5, article id e70264Article in journal (Refereed) Published
Abstract [en]

Bedaquiline is approved for use in a thrice-weekly dosing schedule; simpler once-daily dosing strategies could enable fixed-dose combinations and improve patient adherence. We developed an interactive R Shiny simulation tool to enable the evaluation of different bedaquiline dosing schedules within an integrated dose-pharmacokinetic-efficacy-safety-outcome framework. Four models describing bedaquiline and its metabolite M2 concentrations, time-to-positivity sputum culture results, QTc intervals, and long-term outcomes were incorporated in the framework. A virtual population representative of tuberculosis patients was generated for simulation. Two case studies were investigated: (1) alternative bedaquiline dosing regimens and (2) bedaquiline treatment interruption and reinitiation. The ZeNix once-daily dosing (200 mg once daily for 8 weeks, followed by 100 mg once daily for 16 weeks) yielded 50% lower median bedaquiline and M2 weekly average concentrations compared to the registered (approved) and standard-loading once-daily dosing (400 mg once daily for 2 weeks, followed by 100 mg once daily for 22 weeks) at 2 weeks. The exposure difference was predicted to lead to 11% fewer patients with negative cultures at 2 weeks and 5.8% fewer patients having sputum culture conversions at 8 weeks under the ZeNix dosing. The QTcF intervals were predicted from 376 to 442 ms (5th to 95th percentile of the population) for the three evaluated strategies. We also demonstrated that the Shiny application could guide decisions on the timing and doses for reloading bedaquiline after treatment interruption. The developed Shiny platform supports future exploration of bedaquiline treatment under different scenarios, for example, potential drug-drug interactions and clinical trial simulations.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
bedaquiline, dose selection, simulation tool, tuberculosis
National Category
Pharmaceutical Sciences Microbiology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-586518 (URN)10.1002/psp4.70264 (DOI)001762218000001 ()42118004 (PubMedID)2-s2.0-105038475267 (Scopus ID)
Funder
EU, Horizon 2020
Available from: 2026-05-22 Created: 2026-05-22 Last updated: 2026-06-09Bibliographically approved
Kikstra, N., van Beek, S. W., Maartens, G., Brust, J. C. M., Svensson, E. M. & Koele, S. E. (2026). Bedaquiline reloading strategies following interruptions during daily dosing. Antimicrobial Agents and Chemotherapy, 70(6), 1-6
Open this publication in new window or tab >>Bedaquiline reloading strategies following interruptions during daily dosing
Show others...
2026 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 70, no 6, p. 1-6Article in journal (Refereed) Published
Abstract [en]

Once-daily bedaquiline therapy is a WHO-listed alternative to thrice-weekly dosing for rifampicin-resistant tuberculosis, but, contrary to the thrice-weekly schedule, no guidance exists for treatment re-initiation after interruption. Using a population pharmacokinetic model, we simulated bedaquiline and M2 exposure under various interruption and reloading scenarios. Reloading strategies tailored to interruption duration restored bedaquiline exposure without clinically relevant increases in M2 peak concentrations, providing practical guidance for safe and effective treatment resumption of once-daily bedaquiline therapy.

Place, publisher, year, edition, pages
American Society for Microbiology, 2026
Keywords
pharmacokinetics, reloading, interruptions, bedaquiline, tuberculosis
National Category
Pharmaceutical Sciences Microbiology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-601533 (URN)10.1128/aac.00063-26 (DOI)001753549900001 ()42059380 (PubMedID)2-s2.0-105041218113 (Scopus ID)
Available from: 2026-11-10 Created: 2026-11-10 Last updated: 2026-11-10Bibliographically approved
Abdelwahab, M. T., Svensson, E. M., Diacon, A. H., Conradie, A., Olugbosi, M., Dawson, R., . . . Denti, P. (2026). Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis. Antimicrobial Agents and Chemotherapy, 70(4), Article ID e01399-25.
Open this publication in new window or tab >>Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis
Show others...
2026 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 70, no 4, article id e01399-25Article in journal (Refereed) Published
Abstract [en]

Drug resistance (DR) poses a critical challenge to global efforts to manage tuberculosis (TB). Limited information is available on the combined cardiotoxicity of bedaquiline (BDQ), pretomanid (Pa), and clofazimine (CFZ), key drugs in current DR-TB treatment regimens. All of those prolong the QT interval. We aimed to describe this interaction to predict possible toxicities with established and novel dosing regimens to identify patients at higher risk of QT prolongation. The data for this analysis were obtained from an early-bactericidal activity study in drug-susceptible-TB of several TB drugs. We developed a competitive interaction model to evaluate combined concentration-QTc effect of all three drugs. The model was developed using ECG-matched PK measurements (105 patients, 2,062 observations). The model identified a maximum QT increase by all three drugs of 44.5 ms with respective EC50 values for BDQ, Pa, and CFZ of 0.57, 0.903, and 26.9 mg/L. For patients aged 70 years with non-black ancestry, at risk of increased BDQ exposure, simulations showed that 39.1% had a drug-induced QT change >30 ms after the loading period; this was 29.4% for following BDQ 400 mg daily regimen (part of UNITE4TB program). Reassuringly, no simulations resulted in a QTcF >500 ms, and less than 1% exceeded 480 ms or a change from baseline of >60 ms. We present a joint concentration-QT model of BDQ, Pa, and CFZ. The competitive interaction model serves as a tool to predict possible combined exposure-induced QT prolongation of these drugs in different dosing regimen and identify patients at high risk of significant QT-prolongation.

Place, publisher, year, edition, pages
American Society for Microbiology, 2026
Keywords
tuberculosis, bedaquiline, pretomanid, clofazimine QT interval prolongation, PK/PD modeling
National Category
Pharmacology and Toxicology Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-589165 (URN)10.1128/aac.01399-25 (DOI)001709179900001 ()41801043 (PubMedID)2-s2.0-105034870988 (Scopus ID)
Funder
The Swedish Foundation for International Cooperation in Research and Higher Education (STINT)Wellcome trust, 098316Wellcome trust, 203135/Z/16/ZBill and Melinda Gates Foundation
Available from: 2026-06-10 Created: 2026-06-10 Last updated: 2026-06-10Bibliographically approved
Niward, K., Braian, C., Svärdhagen, G., Augustinsson, D., Öhrnberg, I., Ruslami, R., . . . Schön, T. (2026). Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine: An Approach for Clinical Management. Clinical Infectious Diseases, 82(5), e1045-e1052
Open this publication in new window or tab >>Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine: An Approach for Clinical Management
Show others...
2026 (English)In: Clinical Infectious Diseases, ISSN 1058-4838, E-ISSN 1537-6591, Vol. 82, no 5, p. e1045-e1052Article, review/survey (Refereed) Published
Abstract [en]

Developing shorter treatment regimens for tuberculosis requires careful characterization of the clinical phenotype, which is defined by patient characteristics, radiological extent of disease, mycobacterial burden, drug susceptibility, and host response. Advances in ’omics and model-informed precision dosing, as well as integrated algorithms using artificial intelligence, need to be adapted and validated in clinical trials to improve classification of patients for stratified treatment. When treatment is initiated based on the clinical phenotype, monitoring of treatment response can be improved by quantification of bacterial load, transcriptomic and epigenetic biosignatures for sputum-free monitoring, and assessing disease burden by radiological and symptom scoring tools. Many of these tools are suitable for high-endemic settings. Such integrated monitoring allows prompt drug adjustments for rapid reduction in bacterial load, which prevents development of drug resistance and achieves relapse-free cure even with shorter treatment.

Place, publisher, year, edition, pages
Oxford University Press, 2026
Keywords
tuberculosis, precision medicine, treatment monitoring, stratified treatment, disease severity
National Category
Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-599277 (URN)10.1093/cid/ciaf663 (DOI)001661560100001 ()41537599 (PubMedID)2-s2.0-105039464175 (Scopus ID)
Funder
Swedish Research Council, 2019-05912Swedish Research Council, 2022-05263Swedish Research Council, 2022-00865Swedish Research Council, 2022-04041Swedish Heart Lung Foundation, 2022-0238Swedish Heart Lung Foundation, 2022-0148
Available from: 2026-09-23 Created: 2026-09-23 Last updated: 2026-09-23Bibliographically approved
Wen, H., Sadiq, M. W., Fridén, M., Hohlfeld, J. M., Friberg, L. E. & Svensson, E. M. (2026). Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model. Clinical Pharmacokinetics, 65, 1257-1272
Open this publication in new window or tab >>Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model
Show others...
2026 (English)In: Clinical Pharmacokinetics, ISSN 0312-5963, E-ISSN 1179-1926, Vol. 65, p. 1257-1272Article in journal (Refereed) Published
Abstract [en]

Background: Understanding intrapulmonary pharmacokinetics (PK) following inhalation remains a significant challenge in drug development and repurposing. Current lung sampling methods include bronchoalveolar lavage (BAL), biopsies, and the more recent bronchosorption technique, which enhances regional specificity while reducing potential quantification errors. This study aimed to develop a pulmonary population physiologically based pharmacokinetic (PBPK) model for inhaled salbutamol by integrating data from all three sampling techniques to improve PK predictions and to compare different sampling strategies to optimize future study designs.

Methods: A population-based minimal PBPK model was developed using data from a previously published study (NCT03524066) investigating salbutamol's pulmonary and plasma PK in 13 healthy volunteers after inhalation. Simulations assessed the impact of permeability on pulmonary PK profiles and BAL-derived epithelial lining fluid (ELF)-to-plasma ratios using salbutamol as a reference compound. Stochastic simulation-estimation (SSE) methods were employed to assess the feasibility of different sampling strategies for estimating key parameters of the PBPK model. First, we evaluated using one or two sampling techniques within a single bronchoscopy session. Second, we compared uniform and staggered bronchosorption-based sampling strategies for drugs from different permeability categories.

Results: The minimal PBPK model described pulmonary PK of salbutamol across the lung and estimated the unbound tissue-plasma partition coefficient for the lung (Kp,u,lung) and the effective permeability (Peff) of salbutamol as 11.0 and 0.543 m/h, respectively. Inter-individual variabilities (IIV) were found on plasma clearance and lung deposition fraction. No significant IIV was detected on Kp,u,lung or Peff. Simulations indicated that low-permeability drugs exhibited higher concentrations in the ELF, while high-permeability drugs accumulated more in lung tissues, after inhalation. Results from SSE showed that bronchosorption plus biopsy were the most informative two-technique combination and bronchosorption alone was the best single-technique option. Additionally, the optimal sampling strategy for both uniform and staggered sampling depended on drug permeability, with early time points favoured for high-permeability drugs and later or broader windows needed for low-permeability drugs.

Conclusion: A pulmonary population PBPK model for inhaled salbutamol was developed by integrating detailed intrapulmonary data from bronchoalveolar lavage, biopsy, and bronchosorption. The study revealed that parameter estimates of Kp,u,lung and Peff were sensitive to the sampling technique. Staggered sampling strategies mitigated the risk of biased estimates, though the ideal sampling windows varied by drug's permeability. These findings support model-informed, permeability-driven study design in inhaled drug development.

Place, publisher, year, edition, pages
Springer Nature, 2026
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:uu:diva-602068 (URN)10.1007/s40262-026-01664-y (DOI)001806246600001 ()42371390 (PubMedID)2-s2.0-105043516674 (Scopus ID)
Funder
Uppsala UniversitySwedish Research Council, 2021-02059National Academic Infrastructure for Supercomputing in Sweden (NAISS)Swedish National Infrastructure for Computing (SNIC)Swedish Research Council, 2022-06725
Available from: 2026-10-27 Created: 2026-10-27 Last updated: 2026-10-27Bibliographically approved
McClean, M. C. W., Koele, S. E., Dreisbach, J., Mirold-Mei, S., Njeleka, F., Mapamba, D., . . . Hoelscher, M. (2026). Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials. CPT: Pharmacometrics and Systems Pharmacology (PSP), 15(8), Article ID e70311.
Open this publication in new window or tab >>Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials
Show others...
2026 (English)In: CPT: Pharmacometrics and Systems Pharmacology (PSP), E-ISSN 2163-8306, Vol. 15, no 8, article id e70311Article in journal (Refereed) Published
Abstract [en]

Culture-based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non-culture-based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB-MBLA), could represent a solution. Our objectives were to evaluate TB-MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modeling could provide insight into underlying biological processes. We generated TB-MBLA (LifeArc) data from sputum samples from all 78 patients from the PanACEA BTZ-043 Phase Ib/IIa trial and derived a summary measure of the joint distribution of the three TB-MBLA, colony forming units (CFU), and time-to-positivity (TTP) biomarkers as the first principal component derived from a probabilistic principal component analysis (pPCA). With TB-MBLA marker and the principal component 1 (PC1) values, we reevaluated the original stage IIa dose-response and stages Ib/IIa pharmacokinetics-pharmacodynamics (PK-PD) exposure-response analyses, applying linear and non-linear mixed models, respectively. For TB-MBLA, we could not detect an exposure-response effect in the PK-PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced E max exposure-response between days 0-3 compared with CFU and TTP alone. We also successfully applied pPCA as a modeling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. In this study, we present novel EBA data for the first-in-class antimycobacterial compound BTZ-043 and contextualize the value of emerging bacteriological markers within the EBA trial framework.Trial Registration: ClinicalTrials.gov identifier: NCT04044001

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
biomarkers, BTZ-043, EBA study, machine learning, tuberculosis
National Category
Pharmaceutical Sciences Infectious Medicine Microbiology in the Medical Area
Identifiers
urn:nbn:se:uu:diva-596379 (URN)10.1002/psp4.70311 (DOI)001843025700001 ()42568101 (PubMedID)2-s2.0-105046710360 (Scopus ID)
Funder
EU, Horizon 2020
Available from: 2026-08-27 Created: 2026-08-27 Last updated: 2026-08-27Bibliographically approved
Gafar, F., Svensson, E. M., Yunivita, V., Fregonese, F., Fisher, D., Fox, G. J., . . . Menzies, D. (2026). Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial. Journal of Infectious Diseases, 233(4), e999-e1010
Open this publication in new window or tab >>Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
Show others...
2026 (English)In: Journal of Infectious Diseases, ISSN 0022-1899, E-ISSN 1537-6613, Vol. 233, no 4, p. e999-e1010Article in journal (Refereed) Published
Abstract [en]

Background High-dose rifampicin could potentially shorten tuberculosis preventive therapy (TPT) and improve outcomes. We aimed to characterize population pharmacokinetics of standard- and high-dose rifampicin for TPT among individuals with tuberculosis infection.

Methods Intensive and sparse pharmacokinetic substudies were conducted in Indonesia, Canada, and Vietnam within the 2R2 randomized trial, which compared 2 months of high-dose rifampicin at 20 mg/kg/day (2R20) or 30 mg/kg/day (2R30) with 4 months of standard-dose rifampicin at 10 mg/kg/day (4R10) in adults and adolescents aged >= 10 years. Venous blood samples were collected after 4 weeks of treatment. Rifampicin pharmacokinetics were analyzed using nonlinear mixed-effects modeling in NONMEM.

Results Among 1368 trial participants, 440 were included in model development (51 intensive and 389 sparse sampling), with 191 (43%) assigned to 4R10, 159 (36%) to 2R20, and 90 (20%) to 2R30. A 1-compartment model with saturable hepatic extraction and transit-compartment absorption best described rifampicin pharmacokinetics. All disposition parameters were allometrically scaled using fat-free mass. Country-specific differences, particularly variation in drug formulation, were associated with lower bioavailability in Canada {-21.8% (95% confidence interval [CI] -27.9 to -18.0%)} and Vietnam (-12.3% [95% CI -17.7 to -7.9%]) compared with Indonesia. The 24-hour area under the concentration-time curve increased more than proportionally with dose and was higher across treatment arms in Indonesia, followed by Vietnam and Canada.

Conclusions High-dose rifampicin for TPT resulted in greater-than-proportional increases in exposure due to nonlinear clearance at higher doses. Substantial between-country variability in exposure was observed, which may have been due to multiple factors, including differences in country-specific formulations, fat-free mass, and unmeasured confounders. We developed a pharmacokinetic model of rifampicin for tuberculosis (TB) preventive therapy. High-dose rifampicin showed greater-than-proportional increases in exposure due to saturable clearance, with substantial between-country variability due to multiple factors, including differences in country-specific formulations, fat-free mass, and unmeasured confounders.

Place, publisher, year, edition, pages
Oxford University Press, 2026
Keywords
high-dose rifampicin, population pharmacokinetics, modeling and simulations, tuberculosis preventive treatment, tuberculosis infection
National Category
Pharmaceutical Sciences Pharmacology and Toxicology Public Health, Global Health and Social Medicine Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-592707 (URN)10.1093/infdis/jiag052 (DOI)001698841600001 ()41589392 (PubMedID)2-s2.0-105037585903 (Scopus ID)
Available from: 2026-06-29 Created: 2026-06-29 Last updated: 2026-06-29Bibliographically approved
Calderin, J. M., Nedelman, J., Salinger, D. H., Vongjarudech, T., Denti, P. & Svensson, E. M. (2026). Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers. CPT: Pharmacometrics and Systems Pharmacology (PSP), 15(9), Article ID e70331.
Open this publication in new window or tab >>Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers
Show others...
2026 (English)In: CPT: Pharmacometrics and Systems Pharmacology (PSP), E-ISSN 2163-8306, Vol. 15, no 9, article id e70331Article in journal (Refereed) Published
Abstract [en]

Sorfequiline is a novel diarylquinoline in development for treatment of tuberculosis. In vitro data suggest metabolism via CYP3A4, carrying the potential for presystemic metabolism and drug-drug interactions. Its major metabolite, M3, is pharmacologically active. We developed a semi-mechanistic joint population pharmacokinetic model of sorfequiline and M3 in healthy volunteers. Data were pooled from two studies (CL-001 and CL-002). CL-001 comprised a single-ascending-dose part (10-800 mg suspension fasted plus 100 mg fed), a multiple-ascending-dose part (25, 75, or 200 mg/day for 14 days, fed), and a relative bioavailability assessment including 100 mg in tablet form under fed and fasted conditions. In CL-002, fed participants received 200 mg/day suspension for 8 days followed by 165 mg/day for 4 days. Plasma concentrations were quantified using HPLC-MS/MS, and pharmacokinetic modeling and simulations were conducted in NONMEM. A three-compartment disposition model for both analytes, with transit-compartment absorption, adequately described the data. A fraction of the dose was assumed to be absorbed as M3 due to gut first-pass metabolism. This fraction was 46% (95% CI: 41%-50%) in fasted and 15% (13%-19%) in fed participants. Overall bioavailability decreased by 46% (32%-61%) at fasted doses >= 400 mg. Model-based simulations showed that exposures for all investigated regimens remained below safety reference values. Food reduced the fraction of sorfequiline dose absorbed as M3, likely due to limited gut first-pass metabolism. The developed model provides an initial platform for future pharmacokinetic/pharmacodynamic analyses and simulation of both analytes' exposures under drug-drug interaction scenarios.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
diarylquinoline, joint parent-metabolite modeling, M3, NONMEM, population pharmacokinetics, semi-mechanistic modeling, sorfequiline, TBAJ-876, tuberculosis
National Category
Pharmaceutical Sciences Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-599226 (URN)10.1002/psp4.70331 (DOI)001872753400001 ()42723601 (PubMedID)2-s2.0-105050205567 (Scopus ID)
Available from: 2026-09-25 Created: 2026-09-25 Last updated: 2026-09-25Bibliographically approved
Truter, C., Hamilton, M. S., Le Roux, C., Berndorfler, B., Buys, C., van Niekerk, M., . . . Seddon, J. A. (2026). Understanding ischemia in children with tuberculous meningitis (iThemba): a protocol paper. BMC Pediatrics, 26, Article ID 466.
Open this publication in new window or tab >>Understanding ischemia in children with tuberculous meningitis (iThemba): a protocol paper
Show others...
2026 (English)In: BMC Pediatrics, E-ISSN 1471-2431, Vol. 26, article id 466Article in journal (Refereed) Published
Abstract [en]

Background: One million children develop tuberculosis (TB) each year and a quarter of these die. TB meningitis (TBM) is the most severe form of TB disease and even if diagnosed and treated, 20% die and over 50% of survivors are left with permanent neurological disability. Much of the morbidity and mortality associated with TBM is due to infarction yet, despite this, our understanding of the pathogenesis of infarction in TBM remains limited, especially in children.

Methods: The iThemba study (Understanding ischemia in children with tuberculous meningitis), aims to recruit 100 children with probable or confirmed TBM and obtain samples of blood and cerebrospinal fluid (CSF). All children will undergo MRI and FDG PET/CT at baseline and will have repeat MRI with further blood and CSF samples collected at 2 weeks' follow-up. MRI will then be carried out at 24 weeks with neurodevelopmental assessment at 48 weeks. Neuroimaging will focus on methods to identify and characterize ischemic penumbra and evaluate how this correlates with clinical outcomes. RNA sequencing of blood and CSF will be used to identify differentially expressed genes and identify implicated biological pathways between children with and without infarction. Targeted proteomic profiling will be performed on plasma and CSF to determine differences in protein abundance, with a focus on proteins involved in coagulation and endothelial function. Finally, we will integrate transcriptomic, proteomic and radiomic data to generate a comprehensive understanding of the pathogenesis of infarction in children with TBM. We aim to group children into relevant biological/anatomical phenotypes, each of which may benefit from a different therapeutic approach. Using computer simulation, we will then explore the impact of potential therapeutic interventions on biological pathways for each distinct phenotype. This work may pave the way for the development of point-of-care tests at diagnosis that could allow for stratified novel therapeutic approaches in future.

Discussion: A more comprehensive understanding of the pathophysiology of infarction in children with TBM would permit targeted host-directed therapies, with the potential to moderate or eliminate the consequences of this devastating condition.

Place, publisher, year, edition, pages
Springer Nature, 2026
Keywords
Tuberculous meningitis, Ischemia, Penumbra, Children, Vasculitis, Infarction
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:uu:diva-588687 (URN)10.1186/s12887-026-06598-9 (DOI)001772728600002 ()41820887 (PubMedID)2-s2.0-105039936364 (Scopus ID)
Available from: 2026-06-08 Created: 2026-06-08 Last updated: 2026-06-08Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-0093-6445

Search in DiVA

Show all publications